Research programme: PARP inhibitors - Pfizer

Drug Profile

Research programme: PARP inhibitors - Pfizer

Alternative Names: AG-14361; AG-14447; HYDAMTIQ; Rucaparib - Pfizer; TBI-361

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology
  • Developer GVK BIO; Ono Pharmaceutical; Pfizer
  • Class 3-ring heterocyclic compounds; Azulenes; Benzodiazepines; Isoquinolines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Cerebral ischaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia in Unknown
  • 31 Mar 2011 Preclinical trials in Cerebral ischaemia (unspecified route)
  • 31 Mar 2011 Pharmacokinetics data from an In vitro study presented at the 241st American Chemical Society National Meeting (241st-ACS-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top